Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lisinopril Clear all
Completed Phase 3 Interventional Results available

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

NCT00624065
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol controlled release/lisinopril, lisinopril + placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 17, 2026, 1:37 AM EDT
Completed No phase listed Observational

Modulating Effects of Lisinopril on Sildenafil Activity in Pulmonary Arterial Hypertension(PAH)( MELISSA)

NCT01181284
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 17, 2026, 1:37 AM EDT
Not listed Phase 4 Interventional

Remission From Stage D Heart Failure

NCT01774656
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
Pharmacological Treatment
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Louisville, Kentucky • Omaha, Nebraska • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 17, 2026, 1:37 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors

NCT02623036
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy
Interventions
Equivalent dose enalapril, Equivalent dose lisinopril
Drug
Lead sponsor
Memorial Health University Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.

NCT00549510
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR and lisinopril (FDC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 17, 2026, 1:37 AM EDT
Withdrawn Not applicable Interventional

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

NCT01009944
View directory record Official record
Conditions
Hypertension
Interventions
Lisinopril, Atenolol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study

NCT01380431
View directory record Official record
Conditions
To Determine Bioequivalence Under Fed Conditions
Interventions
Lisinopril
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Phase 2 Interventional Results available

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

NCT00814255
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
17
States / cities
Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.

NCT00557128
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR and lisinopril (FDC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Phase 2 Interventional Results available

Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer

NCT01880528
View directory record Official record
Conditions
Dyspnea, Non-small Cell Lung Cancer, Small Cell Lung Cancer
Interventions
lisinopril, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Cardiovascular Prevention for Persons With HIV

NCT00982189
View directory record Official record
Conditions
HIV Infection, Cardiovascular Disease Risk
Interventions
Pravastatin, Lisinopril
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
40 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 17, 2026, 1:37 AM EDT
Withdrawn Phase 4 Interventional

Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.

NCT03392740
View directory record Official record
Conditions
Cardiomyopathy Due to Drug, Heart Failure, Systolic
Interventions
Lisinopril, Placebo Oral Tablet
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 17, 2026, 1:37 AM EDT
Terminated Phase 1Phase 2 Interventional

Default BP Medication Intensification

NCT01994408
View directory record Official record
Conditions
Hypertension
Interventions
default intensification
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Phase 3 Interventional

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

NCT00004266
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Lisinopril, Nifedipine, Simvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability Study of Lisinopril Tablets, 10 mg

NCT01375244
View directory record Official record
Conditions
Healthy
Interventions
Lisinopril, Zestril
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 17, 2026, 1:37 AM EDT
Terminated Not applicable Interventional Results available

ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

NCT01867047
View directory record Official record
Conditions
Adverse Effects of Angiotensin-converting-enzyme Inhibitors, Hypotension
Interventions
ACE-I Cessation group, ACE-I Continuation group
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 17, 2026, 1:37 AM EDT
Not listed Phase 2 Interventional

Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis

NCT02369926
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Multiple Sclerosis Functional Composite, Mobile Multiple Sclerosis Functional Composite
Procedure
Lead sponsor
Transparency Life Sciences
Industry
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Phase 4 Interventional Results available

ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study

NCT01535235
View directory record Official record
Conditions
HIV
Interventions
Lisinopril, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 17, 2026, 1:37 AM EDT
Active, not recruiting Phase 2 Interventional

Centrally Acting ACE Inhibition in SLE

NCT04486118
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Lisinopril Pills, Benazepril Pill
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Great Neck, New York • Manhasset, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Not applicable Interventional

Cognitive/Cerebrovascular Consequences of HTN Treatment

NCT00151138
View directory record Official record
Conditions
Hypertension
Interventions
Atenolol (drug), Lisinopril (drug)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
35 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2007 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant

NCT01491919
View directory record Official record
Conditions
Hypertension
Interventions
Lisinopril
Drug
Lead sponsor
Uptal Patel
Other
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 17, 2026, 1:37 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 17, 2026, 1:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.

NCT00552708
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR, Lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 17, 2026, 1:37 AM EDT
Terminated Phase 2 Interventional Results available

Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

NCT01234922
View directory record Official record
Conditions
Hypertension, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
lisinopril, losartan potassium, laboratory biomarker analysis, benazepril hydrochloride, ramipril
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 17, 2026, 1:37 AM EDT